Nuclear Medicine and Molecular Imaging, Institut de Cancérologie de Strasbourg Europe (ICANS), Strasbourg University Hospitals, Strasbourg, France.
Molecular Imaging, DRHIM, Institut Pluridisciplinaire Hubert Curien (IPHC), UMR7178, CNRS, University of Strasbourg, Strasbourg, France.
Rev Endocr Metab Disord. 2024 Feb;25(1):187-202. doi: 10.1007/s11154-023-09836-y. Epub 2023 Sep 16.
Due to its rarity and non-specific clinical presentation, accurate diagnosis, and optimal therapeutic strategy of medullary thyroid carcinoma (MTC) remain challenging. Molecular imaging provides valuable tools for early disease detection, monitoring treatment response, and guiding personalized therapies. By enabling the visualization of molecular and cellular processes, these techniques contribute to a deeper understanding of disease mechanisms and the development of more effective clinical interventions. Different nuclear imaging techniques have been studied for assessing MTC, and among them, PET/CT utilizing multiple radiotracers has emerged as the most effective imaging method in clinical practice. This review aims to provide a comprehensive summary of the current use of advanced molecular imaging modalities, with a particular focus on PET/CT, for the management of patients with MTC. It aims to guide physicians towards a rationale for the use of molecular imaging also including theranostic approaches and novel therapeutical opportunities. Overall, we emphasize the evolving role of nuclear medicine in MTC. The integration of diagnostics and therapeutics by in vivo molecular imaging represents a major opportunity to personalize treatment for individual patients, with targeted radionuclide therapy being one representative example.
由于其罕见性和非特异性的临床表现，准确的诊断和最佳的治疗策略仍然是具有挑战性的。分子成像为早期疾病检测、监测治疗反应和指导个性化治疗提供了有价值的工具。通过可视化分子和细胞过程，这些技术有助于深入了解疾病机制和开发更有效的临床干预措施。已经研究了多种核医学成像技术来评估甲状腺髓样癌（MTC），其中，利用多种放射性示踪剂的 PET/CT 已成为临床实践中最有效的成像方法。本综述旨在全面总结目前先进的分子成像方式的应用，特别是 PET/CT，用于 MTC 患者的管理。它旨在指导医生合理使用分子成像，包括治疗方法和新的治疗机会。总的来说，我们强调核医学在 MTC 中的不断发展作用。通过体内分子成像进行诊断和治疗的整合为个体化治疗患者提供了一个重要机会，靶向放射性核素治疗就是一个代表性的例子。
